• Explore /
  • Poster
  • / Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648.

Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648.

Abstract Poster

Authors

null

John A. Bridgewater

University College London Cancer Institute, London, United Kingdom

John A. Bridgewater , Ian Chau , Joseph Gricar , Steven I. Blum , Fiona Taylor , Rachael Lawrance , Brad Padilla , Christine Yip , Lucjan Wyrwicz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT03143153

DOI

10.1200/JCO.2022.40.4_suppl.262

Abstract #

262

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jaffer A. Ajani

First Author: Sylvie Lorenzen

First Author: Richard F. Riedel

First Author: Ian Chau